JP2014509835A5 - - Google Patents

Download PDF

Info

Publication number
JP2014509835A5
JP2014509835A5 JP2013544871A JP2013544871A JP2014509835A5 JP 2014509835 A5 JP2014509835 A5 JP 2014509835A5 JP 2013544871 A JP2013544871 A JP 2013544871A JP 2013544871 A JP2013544871 A JP 2013544871A JP 2014509835 A5 JP2014509835 A5 JP 2014509835A5
Authority
JP
Japan
Prior art keywords
seq
antibody
hvr
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013544871A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014509835A (ja
JP6253987B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/065895 external-priority patent/WO2012087962A2/en
Publication of JP2014509835A publication Critical patent/JP2014509835A/ja
Publication of JP2014509835A5 publication Critical patent/JP2014509835A5/ja
Application granted granted Critical
Publication of JP6253987B2 publication Critical patent/JP6253987B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013544871A 2010-12-20 2011-12-19 抗メソテリン抗体及びイムノコンジュゲート Active JP6253987B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061459962P 2010-12-20 2010-12-20
US61/459,962 2010-12-20
PCT/US2011/065895 WO2012087962A2 (en) 2010-12-20 2011-12-19 Anti-mesothelin antibodies and immunoconjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017018571A Division JP6311042B2 (ja) 2010-12-20 2017-02-03 抗メソテリン抗体及びイムノコンジュゲート

Publications (3)

Publication Number Publication Date
JP2014509835A JP2014509835A (ja) 2014-04-24
JP2014509835A5 true JP2014509835A5 (enExample) 2015-02-12
JP6253987B2 JP6253987B2 (ja) 2017-12-27

Family

ID=45498116

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013544871A Active JP6253987B2 (ja) 2010-12-20 2011-12-19 抗メソテリン抗体及びイムノコンジュゲート
JP2017018571A Active JP6311042B2 (ja) 2010-12-20 2017-02-03 抗メソテリン抗体及びイムノコンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017018571A Active JP6311042B2 (ja) 2010-12-20 2017-02-03 抗メソテリン抗体及びイムノコンジュゲート

Country Status (25)

Country Link
US (3) US8911732B2 (enExample)
EP (2) EP3296321B1 (enExample)
JP (2) JP6253987B2 (enExample)
KR (1) KR20140014116A (enExample)
CN (1) CN107098972A (enExample)
AR (1) AR084356A1 (enExample)
AU (1) AU2011349443B2 (enExample)
BR (1) BR112013014527A2 (enExample)
CA (1) CA2819269A1 (enExample)
CL (2) CL2013001776A1 (enExample)
CO (1) CO6720984A2 (enExample)
CR (1) CR20130335A (enExample)
EA (2) EA028744B1 (enExample)
EC (1) ECSP13012784A (enExample)
IL (1) IL250764A0 (enExample)
MA (1) MA34881B1 (enExample)
MX (1) MX345519B (enExample)
NZ (1) NZ610976A (enExample)
PE (2) PE20170917A1 (enExample)
PH (2) PH12013501323A1 (enExample)
SG (2) SG191294A1 (enExample)
TW (2) TWI477513B (enExample)
UA (2) UA113838C2 (enExample)
WO (1) WO2012087962A2 (enExample)
ZA (2) ZA201303765B (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911732B2 (en) 2010-12-20 2014-12-16 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
KR102023496B1 (ko) 2011-04-21 2019-09-20 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
WO2015032695A1 (en) * 2013-09-09 2015-03-12 Ventana Medical Systems, Inc. Scoring method for mesothelin protein expression
US10640569B2 (en) * 2013-12-19 2020-05-05 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
JP2017518053A (ja) * 2014-06-06 2017-07-06 メモリアル スローン−ケタリング キャンサー センター メソセリン標的化キメラ抗原受容体およびその使用
SG11201706041XA (en) 2015-01-26 2017-08-30 Fate Therapeutics Inc Methods and compositions for inducing hematopoietic cell differentiation
KR20180029201A (ko) 2015-05-18 2018-03-20 티씨알2 테라퓨틱스 인크. 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법
JP6841609B2 (ja) 2015-07-10 2021-03-10 3スキャン インコーポレイテッド 組織学的染色の空間的多重化
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究(慕尼黑)公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究(慕尼黑)公司 Msln及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究(慕尼黑)公司 Flt3及cd3抗體構築體
SG11201801351RA (en) * 2015-08-21 2018-03-28 Carsgen Therapeutics Ltd Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin
KR101782487B1 (ko) * 2015-09-24 2017-09-27 재단법인 목암생명과학연구소 신규 항-메소텔린 항체 및 이를 포함하는 조성물
JP2018536389A (ja) 2015-10-02 2018-12-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト メソテリンとcd3に結合する二重特異性細胞活性化抗原結合分子
EP3371301A4 (en) 2015-11-04 2019-06-26 Fate Therapeutics, Inc. METHOD AND COMPOSITIONS FOR INDUCING THE DIFFERENTIATION OF HEMATOPOIETIC CELLS
WO2017134158A1 (en) 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Psma and cd3 bispecific t cell engaging antibody constructs
US11214618B2 (en) 2016-06-20 2022-01-04 F-Star Therapeutics Limited LAG-3 binding members
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018048975A1 (en) 2016-09-09 2018-03-15 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
IL292551B2 (en) 2016-10-07 2023-10-01 Tcr2 Therapeutics Inc Preparations and methods for reprogramming T-cell receptors using fusion proteins
WO2018098365A2 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP3548515A1 (en) 2016-12-01 2019-10-09 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
US20210079057A1 (en) 2017-06-13 2021-03-18 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CA3070796A1 (en) 2017-07-24 2019-01-31 Regeneron Pharmaceuticals, Inc. Anti-cd8 antibodies and uses thereof
US11548948B2 (en) 2017-12-19 2023-01-10 F-Star Therapeutics Limited FC binding fragments comprising a PD-L1 antigen-binding site
CN110507824A (zh) * 2018-05-21 2019-11-29 荣昌生物制药(烟台)有限公司 一种抗间皮素抗体及其抗体药物缀合物
US12215130B2 (en) * 2018-06-18 2025-02-04 Anwita Biosciences, Inc. Cytokine-albumin binding moiety fusion proteins and uses thereof
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
SG11202100170RA (en) 2018-07-12 2021-02-25 F Star Beta Ltd Antibody molecules that bind pd-l1 and cd137
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
EP3820898B1 (en) 2018-07-12 2025-09-03 invoX Pharma Limited Antibody molecules that bind cd137 and ox40
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CN112955153A (zh) 2018-08-02 2021-06-11 达因疗法公司 肌肉靶向复合物及其用于治疗肌养蛋白病的用途
AU2019327569A1 (en) 2018-08-30 2021-04-29 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
US20220249685A1 (en) * 2019-06-19 2022-08-11 Silverback Therapeutics, Inc. Anti-mesothelin antibodies and immunoconjugates thereof
UY38995A (es) 2019-12-20 2021-06-30 Amgen Inc Constructos de anticuerpo multiespecíficos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores sólidos
EP4175650A1 (en) * 2020-07-06 2023-05-10 Kiromic BioPharma, Inc. Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
WO2022026152A2 (en) * 2020-07-23 2022-02-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CA3195850A1 (en) * 2020-10-18 2022-04-21 May Kung Sutherland Anti-msln binding agents, conjugates thereof and methods of using the same
CN113150128B (zh) * 2020-11-24 2023-01-31 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) 流感病毒np蛋白的单克隆抗体及其应用
EP4333983A4 (en) * 2021-05-07 2025-07-30 Kiromic Biopharma Inc MESOTHELIN ISOFORM-BINDING MOLECULES AND CHIMERIC PD1 RECEPTOR MOLECULES, CELLS CONTAINING THEM AND USES THEREOF
KR102860436B1 (ko) * 2021-06-30 2025-09-19 (주)이노베이션바이오 메소텔린 특이적 항체 및 이의 용도
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
JP2024525613A (ja) * 2021-07-09 2024-07-12 ダイン セラピューティクス,インコーポレーテッド 筋標的化複合体およびジストロフィノパチーを処置するためのその使用
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
IL309936A (en) 2021-07-09 2024-03-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of dystrophinopathy
WO2023283613A1 (en) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20240336681A1 (en) 2021-07-30 2024-10-10 Ludwig-Maximilians-Universität München Anti-cd47 antibodies and use thereof
TW202321296A (zh) 2021-10-06 2023-06-01 美商鏈接免疫療法公司 抗間皮素抗原結合分子及其用途
CN114426582B (zh) * 2022-01-07 2022-11-25 陕西脉元生物科技有限公司 一种神经特异性烯醇化酶单克隆抗体及其制备方法和应用
KR102463078B1 (ko) 2022-01-24 2022-11-03 싸이런테라퓨틱스 주식회사 Muc-1에 특이적으로 결합하는 항체 및 이의 용도
CN119183457A (zh) 2022-04-15 2024-12-24 达因疗法公司 用于治疗强直性肌营养不良的肌肉靶向复合物和制剂
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2024165567A1 (en) * 2023-02-06 2024-08-15 Universite D'aix-Marseille Anti-mesothelin nanobodies, constructs and conjugates
WO2025235862A1 (en) 2024-05-10 2025-11-13 Inndura Therapeutics Inc. A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE171207T1 (de) 1990-10-12 1998-10-15 Us Health Monoklonaler antikörper
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP1514934B1 (en) 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
IL107366A (en) 1992-10-23 2003-03-12 Chugai Pharmaceutical Co Ltd Genes coding for megakaryocyte potentiator
RU2139731C1 (ru) 1992-11-13 1999-10-20 Айдек Фармасьютикалс Корпорейшн (US Способ лечения, антитела, гибридома
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7375183B1 (en) 1996-01-05 2008-05-20 The United States Of America As Represented By The Department Of Health And Human Services Mesothelin, immunogenic peptides derived therefrom, and compositions comprising mesothelin, or immunogenic peptides thereof
ATE254931T1 (de) 1996-01-05 2003-12-15 Us Gov Health & Human Serv Mesothelinantigen, verfahren und testsatz zur targetierung
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
DE69830315T2 (de) 1997-06-24 2006-02-02 Genentech Inc., San Francisco Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
EP1025230B1 (en) 1997-12-01 2006-02-08 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ANTIBODIES, INCLUDING Fv MOLECULES, AND IMMUNOCONJUGATES HAVING HIGH BINDING AFFINITY FOR MESOTHELIN AND METHODS FOR THEIR USE
US6809184B1 (en) 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
CA2312208C (en) 1997-12-05 2011-01-25 The Scripps Research Institute Humanization of murine antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6770445B1 (en) 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
US7745159B2 (en) 1999-02-26 2010-06-29 Nathalie B Scholler Methods and compositions for diagnosing carcinomas
DK2270147T4 (da) 1999-04-09 2020-08-31 Kyowa Kirin Co Ltd Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle
WO2000073346A1 (en) 1999-05-27 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunoconjugates having high binding affinity
US20110104675A1 (en) 1999-08-09 2011-05-05 Pacific Northwest Research Institute Methods and Compositions for Diagnosing Carcinomas
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
MXPA02003456A (es) 1999-10-04 2002-10-23 Medicago Inc Metodo para regular la transcripcion de genes foraneos.
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
WO2001044463A1 (en) 1999-12-15 2001-06-21 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
PT1242438E (pt) 1999-12-29 2007-02-28 Immunogen Inc Agentes citotóxicos compreendendo dixorrubicinas e daunorrubicinas modificadas e seu uso terapêutico
US20020004587A1 (en) 2000-04-11 2002-01-10 Genentech, Inc. Multivalent antibodies and uses therefor
WO2001092581A2 (en) 2000-05-26 2001-12-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2002226930A1 (en) 2000-11-17 2002-05-27 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point
CN101940189A (zh) 2000-11-30 2011-01-12 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
AU2002258518A1 (en) 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7125663B2 (en) 2001-06-13 2006-10-24 Millenium Pharmaceuticals, Inc. Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
AU2002347428A1 (en) 2001-06-18 2003-01-02 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US20050107595A1 (en) 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2455365C (en) 2001-08-03 2014-07-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AU2002323110A1 (en) 2001-08-08 2003-02-24 Incyte Genomics, Inc. Proteins associated with cell growth, differentiation, and death
WO2003035835A2 (en) 2001-10-25 2003-05-01 Genentech, Inc. Glycoprotein compositions
WO2003043583A2 (en) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
WO2003085118A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT CONTAINING ANTIBODY COMPOSITION
DE60336548D1 (de) 2002-04-09 2011-05-12 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック, インコーポレイテッド 合成抗体ファージライブラリー
WO2003101283A2 (en) 2002-06-04 2003-12-11 Incyte Corporation Diagnostics markers for lung cancer
CA2492160A1 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
EP1585767A2 (en) 2003-01-16 2005-10-19 Genentech, Inc. Synthetic antibody phage libraries
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20040180387A1 (en) 2003-03-13 2004-09-16 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
US20050054056A1 (en) 2003-08-05 2005-03-10 Wolfgang Ebel Variant cell surface molecule associated with cancer
CA2542046A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
WO2005035778A1 (ja) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
HRP20100303T1 (hr) 2003-11-05 2010-07-31 Roche Glycart Ag Cd20 antitijela s povećanim afinitetom vezivanja fc receptora i efektorskim djelovanjem
ES2456325T3 (es) 2003-11-06 2014-04-22 Seattle Genetics, Inc. Compuestos de monometilvalina capaces de conjugación con ligandos
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
WO2005072263A2 (en) 2004-01-21 2005-08-11 Fujirebio America, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of mesothelioma
US20060014211A1 (en) 2004-01-21 2006-01-19 Fujirebio Diagnostics, Inc. Detection of mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of the peritoneum and the peritoneal cavity
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
KR101245983B1 (ko) 2004-03-31 2013-06-28 제넨테크, 인크. 인간화 항-tgf-베타 항체
ES2549077T3 (es) 2004-04-07 2015-10-22 Genentech, Inc. Espectrometría de masas de conjugados de anticuerpos
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
ES2403055T3 (es) 2004-04-13 2013-05-13 F. Hoffmann-La Roche Ag Anticuerpos anti-P-selectina
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
MXPA06014771A (es) 2004-06-17 2007-03-21 Mannkind Corp Perfiles de antigeno asociados a tumor en diagnosticos de cancer e inmunoterapia.
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
BRPI0516284A (pt) 2004-09-23 2008-09-02 Genentech Inc anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20070134243A1 (en) 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック, インコーポレイテッド 抗体薬剤結合体および方法
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
US20080125363A1 (en) 2004-12-14 2008-05-29 Enzon Pharmaceuticals Inc. Polymer-Linked Pseudomonas Exotoxin Immunotoxin
CN101080785B (zh) 2004-12-21 2010-05-12 旭硝子株式会社 带透明导电膜的基板的图案形成方法和热处理方法
JP4949373B2 (ja) * 2005-03-10 2012-06-06 モルフォテック、インク. 抗メソテリン抗体
AU2006247565A1 (en) * 2005-05-12 2006-11-23 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Anti-mesothelin antibodies useful for immunological assays
US20090226465A1 (en) 2005-10-31 2009-09-10 Jackson David Y Macrocyclic depsipeptide antibody-drug conjugates and methods
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007112047A2 (en) 2006-03-24 2007-10-04 Enzon Pharmaceuticals, Inc. Formulations containing immunotoxins targeted to the mesothelin tumor cell antigen
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
AU2007254167B2 (en) 2006-05-19 2012-11-15 Technion Research And Development Foundation Ltd. Fusion proteins, uses thereof and processes for producing same
US10118970B2 (en) 2006-08-30 2018-11-06 Genentech, Inc. Multispecific antibodies
WO2008068906A1 (ja) 2006-12-08 2008-06-12 Immuno-Biological Laboratories Co., Ltd 中皮腫診断剤、中皮腫診断キットおよび中皮腫診断方法
AU2007332473B2 (en) 2006-12-14 2012-09-27 Forerunner Pharma Research Co., Ltd. Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
CN101578114A (zh) 2006-12-19 2009-11-11 犹太大学阿尔伯特爱因斯坦医学院 表达病毒抗原的肿瘤细胞的放射免疫疗法和成像
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CA2683568A1 (en) * 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
WO2009045957A1 (en) 2007-10-01 2009-04-09 Medarex, Inc. Human antibodies that bind mesothelin, and uses thereof
EP2215121B1 (en) * 2007-11-26 2016-02-10 Bayer Intellectual Property GmbH Anti-mesothelin antibodies and uses therefor
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
ES2547552T3 (es) 2008-02-01 2015-10-07 Genentech, Inc. Metabolito de nemorrubicina y reactivos análogos, conjugados anticuerpo-fármaco y métodos
WO2009120769A1 (en) 2008-03-27 2009-10-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human anti-mesothelin monoclonal antibodies
WO2010009124A2 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
US8435488B2 (en) 2009-02-27 2013-05-07 Genentech, Inc. Methods and compositions for protein labelling
CA2756393C (en) * 2009-03-24 2017-06-20 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Anti-mesothelin antibodies
UY32560A (es) * 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
CN102933236B (zh) 2010-04-15 2014-10-08 斯皮罗根有限公司 吡咯并苯二氮卓类及其结合物
AU2011265054B2 (en) 2010-06-08 2016-09-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2012055019A1 (en) 2010-10-29 2012-05-03 Urban Surface Solutions Inc. Jet heating device
EP2640727B1 (en) 2010-11-17 2015-05-13 Genentech, Inc. Alaninyl maytansinol antibody conjugates
US8911732B2 (en) 2010-12-20 2014-12-16 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
RU2013140685A (ru) 2011-02-04 2015-03-10 Дженентек, Инк. ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ
WO2012155019A1 (en) 2011-05-12 2012-11-15 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
WO2013055987A1 (en) 2011-10-14 2013-04-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof

Similar Documents

Publication Publication Date Title
JP2014509835A5 (enExample)
JP2017522861A5 (enExample)
JP2016523810A5 (enExample)
JP6010241B2 (ja) Dll3モジュレーター及び使用方法
JP2017534253A5 (enExample)
JP2019146572A5 (enExample)
TWI854953B (zh) 抗cd3抗體及含有該抗體的分子、及其製造方法
JP2015523961A5 (enExample)
HRP20180352T1 (hr) Protutijela anti-fcrh5
JP2017505604A5 (enExample)
CN107847593B (zh) 治疗抗体及其用途
JP2016528882A5 (enExample)
RU2014148162A (ru) Анти-pmel17 антитела и их иммуноконъюгаты
KR20160097336A (ko) 신규 항-dpep3 항체 및 이의 사용 방법
JP2012522513A5 (enExample)
JP2008529497A5 (enExample)
JP2018509146A (ja) Flt3タンパク質に結合する抗体薬物複合体(adc)
JP2008537673A5 (enExample)
JP2015533781A5 (enExample)
CN113906054B (zh) 能够结合cd19和cd3的多特异性抗原结合蛋白及其用途
JP2020522280A5 (enExample)
EP3717007B1 (en) Ildr2 antagonists and combinations thereof
KR20230117183A (ko) 새로운 종양 인게이저 치료 약물의 개발 및 이의 용도
RU2016148616A (ru) Анти-lgr5 антитела и их применение
JP2015529656A5 (enExample)